Supernus Pharmaceuticals (SUPN) Total Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Total Current Liabilities data on file, last reported at $373.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $373.9 million, up 32.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $373.9 million (up 32.71% YoY), and the FY2025 annual result was $338.2 million, up 15.65% from the prior year.
• Total Current Liabilities grew to $373.9 million in Q1 2026 per SUPN's latest filing, from $338.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $735.5 million in Q2 2022 and troughed at $252.6 million in Q2 2023.
• A 5-year average of $400.8 million and a median of $308.7 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 209.31% in 2022, then plunged 65.66% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $688.0 million in 2022, then sank by 57.82% to $290.2 million in 2023, then advanced by 0.76% to $292.4 million in 2024, then climbed by 15.65% to $338.2 million in 2025, then rose by 10.57% to $373.9 million in 2026.
• Business Quant data shows SUPN's Total Current Liabilities at $373.9 million in Q1 2026, $338.2 million in Q4 2025, and $330.6 million in Q3 2025.